Overview of Dr. Hultcrantz
Dr. Malin Hultcrantz is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Karolinska Institute Faculty of Medicine and has been in practice 14 years. She is one of 62 doctors at Memorial Sloan Kettering Cancer Center and one of 8 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Hematology. She has more than 100 publications and over 500 citings.
Office
530 East 74th Street
New York, NY 10021
Education & Training
- Karolinska Institute Faculty of MedicineClass of 2006
Certifications & Licensure
- FL State Medical License 2021 - Present
- NY State Medical License 2016 - 2026
- CT State Medical License 2023 - 2025
- NJ State Medical License 2018 - 2025
Clinical Trials
- Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Roles: Contact
- A Study of Belantamab Mafodotin and Nirogacestat in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment Start of enrollment: 2022 Mar 31
Roles: Contact, Principal Investigator
- A Study of Colesevelam for Lenalidomide-Associated Diarrhea Start of enrollment: 2018 Dec 03
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Up...Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, Kinga Hosszu, Sean M Devlin
Journal of Clinical Oncology. 2024-12-04 - Monoclonal gammopathy of undetermined significance with multiple paraproteins: A population-based screening study.Sæmundur Rögnvaldsson, Jón Þ Óskarsson, Sigrun Thorsteinsdóttir, Malin Hultcrantz, Robert Palmason
Hemasphere. 2024-11-01 - Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States.Malin Hultcrantz, David Kleinman, Ravi Vij, Fernando Escalante, Michel Delforge
Haematologica. 2024-10-17
Press Mentions
- Multicenter Study of Spanish Patients Provides New Insights on COVID-19 in Multiple MyelomaNovember 11th, 2020
- COVID-19 Case Fatality Rate 29 Percent in Multiple Myeloma PatientsAugust 6th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: